Latest Content

The 2025 World Health Organization's (WHO) Global Tuberculosis Report finds progress in prevention, diagnosis, and care—but falling short of targets and curtailed by funding cuts.

This week, read about Merck's advancement of one of its HIV combination therapeutics, Pfizer's influenza vaccine data, the importance of antimicrobial resistance awareness, and more.

Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.

A mother recounts her newborn son's fatal battle with cirrhosis reminding people of the importance of health and education about this vital organ.

Timothy Jenkins, MD, talks about how these important tests are being overly used for respiratory and gastrointestinal presentations and strategies his institution, Denver Health, is employing to reduce testing to save costs and still continuing to achieve optimal treatment outcomes.

David Cameron, PhD, discusses how researchers discovered its antibiotic, Debio 1453, through structure-guided design and advanced it from potent preclinical activity to first-in-human testing.

A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."

Merck’s investigational once-daily, 2-drug HIV regimen, doravirine/islatravir, achieved its primary efficacy and safety end points in a phase 3 trial.

AMR Action Fund CEO Henry Skinner, PhD, MBE, discusses the significance of this week, provides an update on the PASTEUR Act, and explains the differing approaches between Europe and the US with regard to push-pull incentives.

Kaylee Caniff, PharmD, BCIDP, provides insights on a study looking at how urban and rural healthcare settings differ in terms of prescribing.

This form of prophylaxis showed 79% overall effectiveness across 3 European countries.

Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.

This week, learn about the first death from a meat allergy caused by ticks, Gilead reports positive top-line data showing its investigational combination therapy, bictegravir/lenacapavir was efficacious and safe, a discussion around antibiotic alternatives for MRSA, and more.